Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.77 |
| ▸ | LPAR1 | Q92633 | 11/20 | 0.77 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.58 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.56 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.56 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5594633 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1LPAR5LPAR2PLA2G2C | |
| SCHEMBL1191674 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1LPAR5LPAR2PLA2G2C | |
| SCHEMBL10566910 | 0.93 | LPAR3 (0.66) | LPAR3LPAR1LPAR5LPAR2PLA2G2C | |
| SCHEMBL10563405 | 0.93 | LPAR3 (0.66) | LPAR3LPAR1LPAR5LPAR2PLA2G2C | |
| SCHEMBL3217259 | 0.89 | LPAR3 (0.79) | LPAR3LPAR1LPAR5LPAR2LPAR6 | |
| SCHEMBL5610918 | 0.89 | LPAR3 (0.79) | LPAR3LPAR1LPAR5LPAR2LPAR6 | |
| SCHEMBL5610920 | 0.89 | LPAR3 (0.79) | LPAR3LPAR1LPAR5LPAR2LPAR6 | |
| SCHEMBL10566055 | 0.89 | LPAR3 (0.60) | LPAR3LPAR1LPAR5LPAR2PLA2G2C | |
| SCHEMBL7172379 | 0.89 | LPAR3 (0.79) | LPAR3LPAR1LPAR5LPAR2LPAR6 | |
| SCHEMBL10896195 | 0.87 | LPAR3 (1.00) | LPAR3LPAR1LPAR5LPAR2PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918287-A2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1263752-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1427424-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D | 2005-11-24 | — | — | US | disclosed |
| US-6875757-B2 | For therapy of cancer, enhancing cell proliferation, and wound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1427424-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1263752-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003024402-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
| EP-1263752-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001071022-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | LPAR3 3/4885LPAR1 1/4885LPAR5 4/4885 |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | LPAR3 3/4885LPAR1 1/4885LPAR5 4/4885 |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR5 | LPAR3 4/4885LPAR1 1/4885LPAR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.